^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Glioblastoma
    Drug:Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Spandidos Publications
    Title:

    Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

    Excerpt:
    The third patient (male) was diagnosed at the age of 25….Histopathology showed a glioblastoma without epithelioid cells….Immunohistochemistry as well as DNA-sequencing revealed BRAF V600E mutation….Dabrafenib was started with 150 mg twice daily...After one month he reached a nearly complete response...
    DOI:
    https://doi.org/10.3892/or.2017.6013